2 results
Approved WMORecruiting
To assess the time to progression after TACE-DEB and after SBRT in a comparable population of patients diagnosed with HCC.
Approved WMORecruiting
Phase 2:Primary ObjectivesTo determine the recommended Phase3 dose of mitapivat by evaluating the effect of 2 dose levels of mitapivat versus placebo on:• Anemia in subjects with sickle cell disease (SCD)• SafetySecondary ObjectivesTo evaluate the…